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Imunohistochemical detection of an AGE, a ligand for macro- ing sugars, especially D-glucose (GLC), to free-amino
phage receptor, in peritoneum of CAPD patients. groups of proteins [1, 2]. Expression of specific receptors
Background. In patients on long-term continuous ambula- for AGE has been demonstrated on murine and human
tory peritoneal dialysis (CAPD), ultrafiltration (UF) capacity
monocytes/macrophages and bovine and human endo-of peritoneal membrane may be impaired due to accumulation
thelial cells [3–5]. Binding of AGE to receptors on mac-of advanced glycation end products (AGEs). This study aimed
rophages increases the synthesis of cytokines and growthto elucidate the characteristics of a novel anti-AGE antibody,
ODI-GLC19, and to demonstrate AGE accumulation in the factors, resulting in oxidative stress to cells [6]. Three types
peritoneum of CAPD patients using the antibody. of AGE receptors, receptor for AGE (RAGE), galectin
Methods. A monoclonal anti-AGE antibody (ODI-GLC19) 3, and macrophage scavenger receptor (MSR), have beenwas prepared by immunizing female balb/c mice using D-glu-
identified as AGE receptors on macrophages or macro-cose-modified keyhole limpet hemocyanin. The characteristics
phage-derived cells [3–5]. A study using cells overexpress-of ODI-GLC19 were determined by enzyme-linked immuno-
sorbent assay and receptor binding inhibition assay. Immuno- ing MSR showed that MSR is mainly responsible for
histochemistry using ODI-GLC19 was performed to detect AGE uptake of AGE by macrophages [5]. The formation of
in peritoneal tissues obtained from patients with nonrenal dis- macrophage-derived foam cells plays a fundamental role
ease, and CAPD patients with normal and low UF. in the development of early atherosclerotic lesions [7].Results. ODI-GLC19 reacted with glycolaldehyde-modified
The formation of foam cells was induced not only byBSA (GA-BSA) and glucose-modified BSA (GLC-BSA), but
modified LDL but also by AGE and polyanionic macro-not with imidazolone or Nε-(carboxymethyl)lysine. GA-BSA
and GLC-BSA strongly bound to cultured macrophages. Time- molecules [8, 9], although the ligand specificity of AGE
dependent recognition of newly formed GA-BSA by ODI- for MSR remains unclear. AGE accumulation in the
GLC19 was similar to that by macrophages. The binding of peritoneum has been reported to be associated with im-GA-BSA to macrophages was inhibited by ODI-GLC19 in
paired ultrafiltration (UF) capacity in CAPD patientsa dose-dependent manner. Immunohistochemical studies re-
[10, 11].vealed that ODI-GLC19-positive AGE was exclusively de-
tected in peritoneal cells including macrophages, and its stain- In this study, we produced a novel monoclonal anti-
ing intensity was more prominent in the peritoneum of CAPD AGE antibody (ODI-GLC19) by immunizing balb/c
patients, especially with low UF, than in patients with nonrenal mice with keyhole limpet hemocyanin (KLH) glycated
disease. by GLC, and characterized it by enzyme-linked immuno-Conclusions. A novel monoclonal anti-AGE antibody, ODI-
sorbent assay (ELISA). We then determined if the anti-GLC19, recognizes a ligand for an AGE receptor on macro-
body recognizes a ligand for an AGE receptor on macro-phages. Incorporation of AGE into peritoneal cells including
macrophages may be involved in progressive peritoneal dys- phages by receptor binding inhibition assay. Further, we
function in CAPD patients. determined the localization of AGE in the peritoneum
of continuous ambulatory peritoneal dialysis (CAPD)
patients using the antibody.
Advanced glycation end products (AGEs) are late
products formed after nonenzymatic addition of reduc-
METHODS
Preparation of AGE and LDLKey words: advanced glycation end products, AGE receptor, perito-
neum, CAPD. Bovine serum albumin (BSA) was purchased from
Seikagaku Kogyo (Tokyo, Japan); KLH and methylgly- 2003 by the International Society of Nephrology
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oxal (MG) from Sigma Chemical (St. Louis, MO, USA); modified BSA-coated plates. According to the method
of Yazawa S et al [14], GLC-, GA-, GO-, MG-, 3DG-,GLC, glyoxal (GO), and monoiodoacetic acid from
Wako Pure Chemical (Osaka, Japan); and glycolalde- and CM-BSA-coated plates were prepared. The plates
were washed once with PBS containing 0.05% Tween20hyde (GA) from Aldrich Chemical (Milwaukee, WI,
USA). GLC-BSA and GLC-KLH were prepared by in- (PBST). Then, 100 L of each purified antibody or cul-
ture supernatant sequentially diluted with PBST con-cubating BSA or KLH with 0.5 M GLC in 0.4 M phos-
phate buffer (pH 7.4), containing 0.5 mM EDTA, at 37C taining 0.5% BSA was added to the wells and incubated
at 25C for 1.5 hours. After washing three times withfor 100 days. GA-, GO-, MG-, and 3-deoxyglucosone
(3DG)-BSA were prepared by incubating BSA with GA PBST, the plates were incubated with 100 L of ade-
quately diluted HRP-conjugated goat anti-mouse IgM or(0.1 mM), GO (0.1 mM), MG (0.1 mM), and 3DG
(26 mM) in phosphate buffer at 37C for 4, 20, 6, and 38 IgG antibody solution at 25C for 1.5 hours. After wash-
ing three times with PBST, the wells were incubated withdays, respectively. CM-BSA was prepared by incubating
BSA with monoiodoacetic acid at 25C for 2.5 hours, 100 L of citrate-phosphate buffer (pH 5.0) containing
0.1 mg of o-phenylenediamine (Wako Pure Chemicals)according to the method of Wadman SK et al [12]. The
formation of Nε-(carboxymethyl)lysine (CML) was con- and 0.05 L H2O2 (substrate buffer) for color develop-
ment. The reaction was stopped by adding 100 L of 1firmed by amino acid analysis after acid hydrolysis. LDL
(d  1.019–1.063) was isolated from plasma of healthy N H2SO4 solution. Optical density (OD) was measured at
490 nm using a plate reader manufactured by Molecularvolunteers by sequential ultracentrifugation and dialyzed
at 4C against saline (0.15 M NaCl) containing 1 mM Devices (Palo Alto, CA, USA).
ethylene diamine tetraacetic acid (EDTA) (pH 7.4). Oxi-
Receptor binding assaydized LDL (oxLDL) was prepared according to the
method of Ohta T et al [13]. Raw 264.7 mouse macrophages were aliquoted into
12-well plates at a concentration of 5x105 cells per well,
Iodination of modified BSA and cultured at 37C for 18 hours in RPMI1640 media
supplemented with 0.03% glutamine and 10% heat-inac-Fifty micrograms each of GLC-BSA and GA-BSA
were radioiodinated with 0.5 mCi of Na125I using IODO- tivated fetal bovine serum in a humidified atmosphere
of 5% CO2 gas. The wells were washed three times withBEADS iodination reagent (Pierce Chemicals, Rock-
ford, IL, USA) according to the manufacturer’s instruc- PBS, and 1 mL of cold Dulbecco’s modified Eagle’s me-
dium containing 3% BSA was added to each well. Aftertions. 125I-GLC-BSA and 125I-GA-BSA were purified by gel
filtration using a Sephacryl S-300 column (Pharmacia, incubation in an ice bath for 1 hour, 200 L of 125I-GLC-
BSA (approximately 1  106 cells per minute) and 50 LUppsala, Sweden).
of competitors at several concentrations were added to
Preparation of monoclonal anti-AGE antibody the wells and incubated in an ice bath for 3 hours. After
sequential washing three times with PBS containing 1%Female balb/c mice were immunized subcutaneously
with 20 g of GLC-KLH in Freund’s complete (for the BSA and 3 times with PBS, 1 mL of 0.1 M NaOH solution
was added to each well and incubated at 37C for 1 hour.first injection) or incomplete (for the second and later
injections) adjuvant (Difco Lab., Detroit, MI, USA), and The NaOH solution in each well was transferred to a
tube, and radioactivity was measured by a -counter.immunizations were repeated at two-week intervals until
the antibody titer had increased sufficiently. Three days
Preparation of GA-BSA with variousafter final immunization, the splenocytes from immu-
incubation periodsnized mice were fused with P3U1 mouse myeloma cells
using polyethylene glycol (Boehringer Mannheim, Mann- BSA (10 mg/mL) was incubated with 100 mM GA in
0.1 M PB buffer (pH 7.4) at 37C for 0, 0.5, 1, 2, 4, 8, 12,heim, Germany). Antibody screening was performed by
ELISA using GLC-BSA coated plates. The hybridoma or 24 hours. As soon as the incubations were finished,
the reaction mixtures were applied to a PD-10 columncells producing antibodies to GLC-BSA (ODI-GLC19,
IgM) were cloned by a limiting dilution technique. (Pharmacia, Uppsala, Sweden) and eluted with PBS con-
taining 1 mM EDTA buffer to remove excess GA. Each
Characterization of ODI-GLC19 GA-BSA eluted was pooled, and protein concentra-
tions were measured by BCA assay (Pierce Chemicals,Horseradish peroxidase (HRP)-conjugated anti-mouse
IgM goat antibody was purchased from Bio Source Inter- Rockford, IL, USA) according to the manufacturer’s
instructions.national (Camarillo, CA, USA), HRP-conjugated anti-
mouse IgG goat antibody from Bio Rad (Hercules, CA,
Competitive ELISAUSA), and microtitration plates (96-well; Nunc Maxi-
sorp) from Gibco Laboratories (Grand Island, NY, USA). Fifty microliters of GA-BSA and 50 L of adequately
diluted ODI-GLC19 solution were added to wells of theODI-GLC19 was characterized by ELISA using various
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Fig. 2. Characterization of ODI-GLC19 by ELISA. GLC-BSA (),
CM-BSA (), GA-BSA (), GO-BSA (), MG-BSA (), or 3DG-
BSA ()-coated plates were used.
Fig. 1. Competitive inhibition assay using Raw 264.7 macrophages.
125I-GLC-BSA was incubated with GLC-BSA (), CM-BSA (), GA-
BSA (), GO-BSA (), MG-BSA (), 3DG-BSA (), oxLDL (), low-UF patients (102  95 vs. 84  32 months and
LDL () or BSA (X) in Raw 264.7 macrophages culture wells. The 44  21 vs. 60  14 months, respectively). To determine
results are expressed as B/B0 (%), where B is the binding of 125I-GLC-
localization of AGE, we performed immunohistochemi-BSA to the cells in the presence of each competitor, and B0 is the
binding of 125I-GLC-BSA in the absence of the competitor. cal staining of the peritoneum using HRP-labeled ODI-
GLC19. In brief, thin sections (2 M) from paraffin-
embedded peritoneal tissues were deparaffinized and
treated with 0.1% proteinase K (37C, 30 minutes) prior
GA-BSA coated plates and incubated at 25C for 1.5 to staining procedure. Endogenous peroxidase activity
hours. After washing three times with PBST, 100 L was blocked by incubating the sections with 0.3% H2O2
of adequately diluted HRP-conjugated goat anti-mouse in methanol at room temperature for 10 minutes. Then,
IgM or IgG antibody solution was added to the wells the sections were incubated with the antibody solution
and incubated at 25C for 1.5 hours. After washing three at 4C overnight. After washing with PBS, localization of
times with PBST, color development was carried out and peroxidase was directly revealed using diaminobenzidine
OD was measured at 490 nm. tetrahydrochloride (DAB). The sections were counter-
stained with 1% methylgreen solution after giving theReceptor binding inhibition assay for GA-BSA
target brown color by DAB. The staining intensity ofwith ODI-GLC19
ODI-GLC19-positive AGE was scored using a semi-
125I-GA-BSA (200 L) was incubated with 200 L of quantitative scale (0 to ).
ODI-GLC19 (1 g/tube or 0.1 g/tube) at 4C for 16
hours. Each reaction mixture was transferred to Raw
RESULTS264.7 mouse macrophages culture wells, and incubated in
an ice bath for three hours. The subsequent assay was To examine the binding of various modified proteins
performed according to the method previously described. and oxLDL to Raw 264.7 macrophages, competitive in-
hibition assay was performed. As shown in Fig. 1, the
Immunohistochemistry for AGE in peritoneum of binding of 125I-GLC-BSA was clearly inhibited by GA-,
CAPD patients GLC-BSA, and oxLDL. Inhibition of the binding of GA-
Peritoneal tissues were obtained from autopsy cases, BSA was much stronger than that of GLC-BSA and
consisting of four patients with nonrenal disease, four oxLDL. CM- and 3DG-BSA did not show any inhibitory
CAPD patients with normal UF, and three CAPD pa- activity.
tients with low-UF capacity. The grade of UF capacity The specificity of ODI-GLC19 was characterized by
was determined by referring to their clinical courses dur- ELISA using various AGE-BSA-coated plates. ODI-
ing CAPD. There were no significant differences in age GLC19 recognizes GA- and GLC-BSA. However, ODI-
GLC19 did not react with CM- or 3DG-BSA (Fig. 2).between these groups (nonrenal disease, 57 19; normal
UF, 52  15; low UF, 59  10 years old, [mean  SD]). Therefore, recognition of modified proteins by ODI-
GLC19 was similar to that by cultured macrophagesThere were no significant differences in total duration
on dialysis and duration on CAPD between normal- and (Fig. 1).
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Fig. 4. Receptor-binding inhibition of 125I-GA-BSA by ODI-GLC19.
The binding of 125I-GA-BSA to Raw 264.7 macrophages competed with
ODI-GLC19. The results are expressed as B/B0 (%), where B is the
binding of 125I-GA-BSA to macrophages in the presence of the antibody,
and B0 is the binding of 125I-GA-BSA in the absence of the antibody.
an AGE, a ligand which binds to an AGE receptor on
macrophages.
Figure 5 and Table 1 show the results of immunostain-
ing peritoneum using ODI-GLC19. ODI-GLC19-posi-
tive AGE was markedly accumulated in the peritoneum
of CAPD patients, especially with low UF, as compared
with patients with nonrenal disease, (Table 1; Fig. 5 A
and B). ODI-GLC19-positive AGE was detected within
the peritoneal cells, but never in extracellular regions,
such as collagen (Fig. 5B).
Fig. 3. Changes in GA-BSA formation recognized by ODI-GLC19 and
Raw 264.7 macrophages for various incubation periods. (A) Results are DISCUSSION
expressed as B/B0 (%), where B is the binding of the antibody to the
In the present study, we produced a monoclonal anti-GA-BSA coated plates, or the binding of 125I-GLC-BSA to macrophages
in the presence of the competitor (newly formed GA-BSA), and (B) AGE antibody, ODI-GLC19. The antibody recognizes
B0 is the binding of 125I-GLC-BSA in the absence of the competitor. an AGE, which binds to an AGE receptor on macro-
phages, although the chemical structure of the epitope
still remains unclear. Further, we demonstrated a marked
accumulation of ODI-GLC19-positive AGE in perito-The binding of GA-BSA to ODI-GLC19 and to Raw
neal cells in CAPD patients, especially in those with264.7 macrophages was determined using GA-BSA by
low UF.competitive ELISA and receptor binding assay, respec-
Accumulation of AGE has been observed in lens crys-tively. The binding of GLC-BSA to macrophages (Fig.
talline [15, 16], collagen [17], renal mesangial cells [17],3A) and that of ODI-GLC19 to GA-BSA-coated plate
and atherosclerotic lesions [18, 19]. Cell-surface AGE re-(Fig. 3B) were both inhibited by newly formed GA-BSA.
ceptors such as RAGE, galectin 3, and MSR have beenThe time-dependence of the GA-BSA recognition by
identified on circulating monocytes, endothelial cells, andODI-GLC19 was similar to that of macrophages. To
renal mesangial cells [3–5]. Mouse macrophage cell linefurther clarify the relationship between the epitope rec-
Raw 264.7 expresses MSR and galectin 3 on its surfaceognized by ODI-GLC19 and the ligand of AGE recep-
[20]. GA-, GLC-, GO-, and MG-modified proteins exhib-tors on Raw 264.7 macrophages, receptor binding inhibi-
ited strong or moderate binding reactivity with macro-tion assay was performed (Fig. 4). ODI-GLC19 dose-
phages, whereas 3DG- and CM-modified proteins diddependently prevented 125I-GA-BSA from binding to
Raw 264.7 macrophages. Thus, ODI-GLC19 recognizes not. The binding ability of GA-, GLC-, GO-, and MG-
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Table 1. Number of ODI-GLC19-positive cells in peritoneum
underneath the mesothelial layer
Number of positive cells
 10 2/mm2
Nonrenal disease Normal UF Low UF
(N  4) (N  4) (N  3)
63 94a 166b,c
a P  0.05
b P  0.0001 vs. nonrenal disease
c P  0.0001 vs. normal UF
ODI-GLC19-positive AGE was increased in the perito-
neum of CAPD patients, especially in low-UF patients,
compared with that of patients with nonrenal disease.
However, the staining was exclusively localized in the
peritoneal cells, in contrast to imidazolone, which was
detected in degenerative collagen [10]. Peritoneal cells
positive for ODI-GLC19 were mostly myofibroblasts and
macrophages (data are not included). ODI-GLC19-posi-
tive AGE incorporated into the peritoneal cells may
play an important role in progressive deteriorating UF
capacity.
In conclusion, ODI-GLC19 recognizes a ligand of an
AGE receptor on macrophages. ODI-GLC19-positive
AGE accumulated in the peritoneum of CAPD patients
may be involved in progressive peritoneal dysfunction.
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Fig. 5. Light microscopic pictures of peritoneal membrane stained by Showa-ku, Nagoya 466-8560, Japan.
ODI-GLC19. (A) Peritoneal membrane in a patient with nonrenal dis- E-mail: tniwa@med.nagoya-u.ac.jp
ease (39-year-old female). Original magnification 50. (B) Thickened
peritoneal membrane with proliferation of myofibroblasts and macro-
phages in a CAPD patient with low UF (52-year-old male). Original REFERENCES
magnification 50)
1. Brownlee M, Cerami A, Vlassara H: Advanced glycosylation
end products in tissue and the biochemical basis of diabetic compli-
cations. N Engl J Med 318:1315–1321, 1988
2. Monnier VM, Cerami A: Nonenzymatic browning in vivo: possible
process for aging of long-lived proteins. Science 211:491–493, 1981modified proteins to the cells was consistent with the
3. Neeper M, Schmidt AM, Brett J, et al: Cloning and expressionfindings of Nagai R et al [21]. ODI-GLC19 mainly recog-
of a cell surface receptor for advanced glycosylation end products
nized GA- and GLC-modified proteins. However, it did of proteins. J Biol Chem 267:14998–15004, 1992
4. Vlassara H, Li YM, Imani F, et al: Identification of galectin-3 asnot react with 3DG- or CM-modified proteins, indicating
a high-affinity binding protein for advanced glycation end productsthat it does not recognize imidazolone or CML. The
(AGE): A new member of the AGE-receptor complex. Mol Med
AGE recognition by this antibody was similar to AGE 1:634–646, 1995
5. Araki N, Higashi T, Mori T, et al: Macrophage scavenger receptorrecognition by macrophages. Time-dependent recogni-
mediates the endocytic uptake and degradation of advanced glyca-tion by ODI-GLC19 and cultured macrophages was simi-
tion end products of the Mailard reaction. Eur J Biochem 230:408–
lar during GA-modified protein formation. Moreover, 415, 1995
6. Yan SD, Schmidt AM, Anderson GM, et al: Enhanced cellularODI-GLC19 dose-dependently inhibited the binding of
oxidant stress by the interaction of advanced glycation end prod-GA-BSA to macrophages. These findings suggest that a
ucts with their receptors/binding proteins. J Biol Chem 269:9889–
common structure of AGE is recognized by both ODI- 9897, 1994
7. Yla¨-Herttuala S, Palinski W, Rosenfeld ME, et al: EvidenceGLC19 and Raw 264.7 macrophages.
for the presence of oxidatively modified low density lipoproteinAGE accumulation in the peritoneum has been re-
in atherosclerotic lesions of rabbit and man. J Clin Invest 84:1086–
ported to be associated with impaired UF capacity in 1095, 1989
8. Goldstein JL, Ho YK, Basu SK, Brown MS: Binding site onCAPD patients [10, 11]. The heat-sterilization process
macrophages that mediates uptake and degradation of acetylatedof PD fluids produces high concentration of glucose deg-
low density lipoprotein, producing massive cholesterol deposition.
radation products (GDPs) [22, 23], which are responsible Proc Natl Acad Sci USA 76:333–337, 1979
9. Suginohara Y, Miyazaki A, Hakamata H, et al: The heparin-for increased AGE formation [24, 10]. Accumulation of
Nakamura et al: Peritoneal AGE binding to macrophages S-157
bound fraction of human lipoprotein-deficient serum inhibits endo- in diabetic renal glomerular lesions. Implication for glycoxidative
stress in the pathogenesis of diabetic nephropathy. J Clin Investcytic uptake of oxidized low density lipoprotein by macrophages.
100:2995–3004, 1997Atherosclerosis 120:167–179, 1996
18. Niwa T, Katsuzaki T, Miyazaki S, et al: Immunohistochemical10. Nakamura S, Miyazaki S, Sasaki S, et al: Localization of Imidazo-
detection of imidazolone, a novel advanced glycation end product,lone in the peritoneum of CAPD patients: A factor for a loss of
in kidneys and aortas of diabetic patients. J Clin Invest 99:1272–ultrafiltration. Am J Kidney Dis 38:S107–S110, 2001
1280, 199711. Honda K, Nitta K, Horita S, et al: Accumulation of advanced
19. Sakata N, Imanaga Y, Meng J, et al: Immunohistochemical local-glycation end products in the peritoneal vasculature of continuous
ization of different epitopes of advanced glycation end productsambulatory peritoneal dialysis patients with low ultra-filtration.
in human atherosclerotic lesions. Atherosclerosis 141:61–75, 1998Nephrol Dial Transplant 14:1541–1549, 1999
20. Radoff S, Vlassara H, Cerami A: Characterization of a solubi-12. Wadman SK, De Bree PK, Van Sprang FJ, et al: Nε-(carboxy-
lized cell surface binding protein on macrophages specific for pro-methyl)lysine, a constituent of human urine. Clin Chim Acta 59:313–
teins modified nonenzymatically by advanced glycosylated end320, 1975
products. Arch Biochem Biophys 263:418–423, 198813. Ohta T, Takata K, Horiuchi S, et al: Protective effect of lipopro-
21. Nagai R, Matsumoto K, Ling X, et al: Glycolaldehyde, a reactiveteins containing apoprotein A-I on Cu2-catalyzed oxidation of
intermediate for advanced glycation end products, plays an impor-human low density lipoprotein. FEBS Lett 257:435–438, 1989
tant role in the generation of an active ligand for the macrophage14. Yazawa S, Akamatsu S, Tachikawa T, et al: Development and
scavenger receptor. Diabetes 49:1714–1723, 2000characterization of a novel anti-fucosylated antigen monoclonal 22. Kjellstrand P, Martinson E, Wieslander A, Holmquist B:
antibody YB-2 and its usefulness in the immunohistochemical diag- Development of toxic degradation products during heat steriliza-
nosis of colorectal cancer. Jpn J Cancer Res 84:641–648, 1993 tion of glucose-containing fluids for peritoneal dialysis: Influence
15. Ahmed MU, Thorpe SR, Baynes JW: Identification of Nε-carboxy- of time and temperature. Perit Dial Int 15:26–32, 1995
methyllysine as a degradation product of fructoselysine in glycated 23. Schalkwijk CG, Posthuma N, ten Brink HJ, et al: Induction of
protein. J Biol Chem 261:4889–4894, 1986 1, 2-dicarbonyl compounds, intermediates in the formation of ad-
16. Ahmed MU, Brinkmann Frye E, Degenhardt TP, et al: Nε-(car- vanced glycation endproducts, during heat-sterilization of glucose-
boxyethyl)lysine, a product of the chemical modification of proteins based peritoneal dialysis fluids. Perit Dial Int 19:325–333, 1999
by methylglyoxal, increases with age in human lens proteins. Bio- 24. Tauer A, Knerr T, Niwa T, et al: In vitro formation of N(epsilon)-
chem J 324:565–570, 1997 (carboxymethyl)lysine and imidazolones under conditions similar
17. Horie K, Miyata T, Maeda K, et al: Immunohistochemical colocali- to continuous ambulatory peritoneal dialysis. Biochem Biophys
Res Commun 280:1408–1414, 2001zation of glycoxidation products and lipid peroxidation products
